Ikarian Capital’s Upstream Bio Inc UPB Stock Holding History

Ikarian Capital’s Portfolio UPB Stock Details UPB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-161,113	Closed	-$3.03M	–	231
2025 Q3	$3.03M	Buy	+161,113	New	+$2.5M	0.31%	82

Other funds holding UPB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Ikarian Capital's UPB Position: Q4 2025 in Review

Ikarian Capital sold out of Upstream Bio Inc (UPB) in Q4 2025, closing a stake of 161,113 shares — an estimated $3.03M sold.

Ikarian Capital first reported a position in UPB in Q3 2025 and held it in 1 quarter. The position peaked at $3.03M in Q3 2025. 133 funds tracked by Wall St. Rank hold UPB as of Q4 2025.

Ikarian Capital reported no remaining Upstream Bio Inc position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 161,113 Upstream Bio Inc shares in Q4 2025, an estimated $3.03M.
Ikarian Capital first reported a position in Upstream Bio Inc in Q3 2025 and held it in 1 quarter.
Ikarian Capital's Upstream Bio Inc position peaked at $3.03M in Q3 2025.
133 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.